GLP1R and obesity disorder: Reducing CVD risk in individuals with obesity is therefore a critical public health priority, highlighting the potential role of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) based therapies in addressing both obesity and its related cardiovascular complications.